LAPS-GCSF: Phase II started

Spectrum began an open-label, dose-ranging Phase II trial to compare 45, 135 and 270 µg/kg subcutaneous SPI-2012 given on day 2 of each 21-day cycle vs. Neulasta pegfilgrastim in about 144 breast canc...